港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫美概念股

688.562

-7.784-1.12%

漲家數：4

跌家數：6

平家數：3

市盈率：- -

高：701.617

開：697.082

低：683.143

收：696.346

資料載入中...

復星醫藥新董事長“接棒”！公司一季度成績單“出爐”

国际金融报

復星醫藥董事長換帥

赛柏蓝器械

復星醫藥(02196)4月30日耗資996.983萬港元回購70.95萬股

CDBeauty與四環醫藥達成戰略合作：構築多元美學領航美業新生態

企业观察网

康哲藥業擬分拆德鎂醫藥上市，聚焦皮膚健康駛入增長“快車道”

环球财富网

四環醫藥04月30日主力淨流出164.9萬元散户資金買入

復鋭醫療科技04月30日遭主力拋售240.1萬元

康哲藥業04月30日獲主力加倉177.5萬元

復星醫藥04月30日主力淨流出979.1萬元散户資金買入

三生製藥(01530)下跌2.94%，報11.9元/股

豫健生物、復星醫藥強強聯合，25億醫學城星未來基金正式設立

大河财立方

四環醫藥(00460)出現大手賣出250萬股，成交價$0.73，涉資182.5萬

阿斯达克财经

21健訊Daily | 接棒吳以芳，陳玉卿出任復星醫藥董事長；阿斯利康一季度收入135.88億美元

21世纪经济报道

復星醫藥換帥：陳玉卿接棒吳以芳任董事長，吳以芳改任復星國際執行總裁

復星醫藥控股企業簽訂合夥協議

格隆汇资讯

復星醫藥(02196)控股企業蘇州君明擬出資4.9億元參設私募股權投資基金

復星醫藥(02196)控股子公司復宏漢霖與 Sandoz AG 簽訂《合作與許可協議》

復星醫藥控股子公司復宏漢霖與 Sandoz AG簽訂《合作與許可協議》

復星醫藥(02196)選舉陳玉卿擔任董事會董事長

接棒吳以芳，陳玉卿出任復星醫藥(02196)董事長

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1593/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"醫美概念股","latestPrice":688.5618,"timestamp":1746000495768,"preClose":696.34595,"halted":0,"volume":104740800,"delay":0,"changeRate":-0.011179,"floatShares":0,"shares":0,"eps":0,"marketStatus":"勞動節休市","change":-7.784119,"latestTime":"04-30 16:00:00","open":697.0822,"high":701.6172,"low":683.14325,"amount":647892482,"amplitude":0.02653,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"pbRate":1.22863,"peRate":18.97188,"turnoverRate":0.005095,"increases":4,"decrements":6,"flats":3,"marketCap":117115448592,"floatMarketCap":82728321936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":701.6172,"amplitude":0.02653,"preClose":696.34595,"low":683.14325,"pbRate":"1.22863","latestPrice":688.5618,"volume":104740800,"delay":0,"open":697.0822,"prevYearClose":571.87146,"prevWeekClose":717.241,"prevMonthClose":677.607,"prevQuarterClose":677.607,"fiveDayClose":711.287,"twentyDayClose":701.326,"sixtyDayClose":538.497,"secType":"PLATE","market":"HK","turnoverRate":0.005095,"peRate":18.97188,"marketCap":117115448592,"floatMarketCap":82728321936,"timestamp":1746000495768,"nameCN":"醫美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":4,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531036542","title":"復星醫藥新董事長“接棒”！公司一季度成績單“出爐”","url":"https://stock-news.laohu8.com/highlight/detail?id=2531036542","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531036542?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 19:19","pubTimestamp":1746011940,"startTime":"0","endTime":"0","summary":"4月29日盘后，复星医药发布2025年第一季度报告和新的董事会分工情况。今年第一季度复星医药营收94.2亿元，同比下滑7.26%；归母净利润7.65亿元，同比增长25.42%。2020年10月，吴以芳经选举担任复星医药第八届董事会董事长，至今已四年有余。一季度成绩单“出炉”业绩层面，复星医药2025年一季报已经披露。研发成果上，今年第一季度复星医药自主研发及许可引进的2个创新药分别在中国和欧盟获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043019270794e8e698&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043019270794e8e698&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","BK1593","600196"],"gpt_icon":0},{"id":"2531038740","title":"復星醫藥董事長換帥","url":"https://stock-news.laohu8.com/highlight/detail?id=2531038740","media":"赛柏蓝器械","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531038740?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 18:09","pubTimestamp":1746007740,"startTime":"0","endTime":"0","summary":"公告显示，一季度复星医药实现营业收入94.20亿元，同比下降7.26%；归母净利润7.65亿元，同比增长25.42%；经营活动现金流10.56亿元。今年3月，复星医药与和睦家在合作长达16年后正式“分手”。2024年复星医药医疗器械与医学诊断业务收入43.23亿，占营业收入比重10.53%。健嘉医疗由复星医药集团及国药控股共同出资设立。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-04-30/doc-ineuxwex0331969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600196","BK0183","BK0012","BK0096","BK0187","02196","BK1515","BK0188","BK0196","BK1191","BK0028","BK0060","BK0175","BK0239","BK1593"],"gpt_icon":0},{"id":"2531085457","title":"復星醫藥(02196)4月30日耗資996.983萬港元回購70.95萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085457","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531085457?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:40","pubTimestamp":1746006043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，2025年4月30日耗资996.983万港元回购70.95万股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0096","BK0183","BK1593","02196","BK0060","BK1515","BK0012","BK0196","BK0188","BK0239","BK0175","BK1191","BK0187","600196","BK0028"],"gpt_icon":0},{"id":"2531089274","title":"CDBeauty與四環醫藥達成戰略合作：構築多元美學領航美業新生態","url":"https://stock-news.laohu8.com/highlight/detail?id=2531089274","media":"企业观察网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531089274?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 17:14","pubTimestamp":1746004440,"startTime":"0","endTime":"0","summary":"2025年4月29日，CDBeauty正式宣布与国内医药行业领军企业四环医药达成深度战略合作，成为国内首家与头部医药集团建立战略伙伴关系的跨性别美学机构。CDBeauty与四环医药代表合影以创新之力赋能多元美学，共筑行业包容性未来CDBeauty作为国内No.1跨性别美学品牌，始终以“多元美学·无界共生”为核心理念，致力于为跨性别者、性别多元群体提供安全、专业的变美服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171557974b5f4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430171557974b5f4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","00460","BK1191","BK1593","BK1515"],"gpt_icon":0},{"id":"2531089032","title":"康哲藥業擬分拆德鎂醫藥上市，聚焦皮膚健康駛入增長“快車道”","url":"https://stock-news.laohu8.com/highlight/detail?id=2531089032","media":"环球财富网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531089032?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:39","pubTimestamp":1746002384,"startTime":"0","endTime":"0","summary":"近日，康哲药业建议启动分拆，拟推动旗下皮肤业务子公司德镁医药于香港联交所主板独立上市，引发资本市场广泛关注。2024年，其皮肤处方药收入亦排名首位。值得注意的是，德镁医药2024年皮肤学级护肤品收入同比增长68%，占比提升至13%，显示出其“药妆协同”战略的成效。随着更多核心产品获批、渠道拓展深化，德镁医药有望进一步夯实其在皮肤健康赛道的领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430164718974b5635&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430164718974b5635&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00867","09939","BK1574","SG9999004220.SGD","BK1161","SG9999015945.SGD","IE00BMCWC346.EUR","BK1515","SG9999015986.USD","LU2488822045.USD","SG9999015952.SGD","IE00BYV24P56.USD","BK1191","BK1593","SG9999015978.USD"],"gpt_icon":0},{"id":"2531276089","title":"四環醫藥04月30日主力淨流出164.9萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531276089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531276089?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000933,"startTime":"0","endTime":"0","summary":"04月30日, 四环医药股价跌1.37%，报收0.72元，成交金额3998.6万元，换手率0.59%，振幅6.85%，量比1.45。四环医药今日主力资金净流出164.9万元，上一交易日主力净流入1312.1万元。该股近5个交易日上涨9.23%，主力资金累计净流入1931.3万元；近20日主力资金累计净流入5340.5万元，其中净流入天数为13日。该股主力净额占比0.03%，港股市场排名2528/2646。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170749a46d746d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170749a46d746d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","BK1515","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"2531085159","title":"復鋭醫療科技04月30日遭主力拋售240.1萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531085159","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531085159?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000913,"startTime":"0","endTime":"0","summary":"04月30日, 复锐医疗科技股价跌1.38%，报收4.30元，成交金额419.0万元，换手率0.21%，振幅2.98%，量比1.80。复锐医疗科技今日主力资金净流出240.1万元，连续5日净流出，上一交易日主力净流出45.9万元。该股近5个交易日下跌5.08%，主力资金累计净流出389.3万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出595.0万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170244a46d7257&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170244a46d7257&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1100","BK1593","01696"],"gpt_icon":0},{"id":"2531089772","title":"康哲藥業04月30日獲主力加倉177.5萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531089772","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531089772?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000912,"startTime":"0","endTime":"0","summary":"04月30日, 康哲药业股价涨1.47%，报收8.30元，成交金额5070.4万元，换手率0.25%，振幅2.57%，量比0.42。康哲药业今日主力资金净流入177.5万元，上一交易日主力净流入183.8万元。该股近5个交易日下跌0.63%，主力资金累计净流入773.2万元；近20日主力资金累计净流入1888.1万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170226a6ce97fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170226a6ce97fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999015986.USD","SG9999015945.SGD","LU2488822045.USD","SG9999004220.SGD","BK1191","SG9999015952.SGD","00867","IE00BYV24P56.USD","IE00BMCWC346.EUR","SG9999015978.USD","BK1593"],"gpt_icon":0},{"id":"2531003107","title":"復星醫藥04月30日主力淨流出979.1萬元 散户資金買入","url":"https://stock-news.laohu8.com/highlight/detail?id=2531003107","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531003107?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 16:15","pubTimestamp":1746000906,"startTime":"0","endTime":"0","summary":"04月30日, 复星医药股价跌3.72%，报收13.98元，成交金额1.3亿元，换手率1.65%，振幅3.31%，量比2.23。复星医药今日主力资金净流出979.1万元，上一交易日主力净流入309.8万元。该股近5个交易日下跌4.92%，主力资金累计净流出592.3万元；近20日主力资金累计净流入198.8万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170143a6ce97c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430170143a6ce97c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2531877778","title":"三生製藥(01530)下跌2.94%，報11.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2531877778","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531877778?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 14:51","pubTimestamp":1745995872,"startTime":"0","endTime":"0","summary":"4月30日，三生制药(01530)盘中下跌2.94%，截至14:51，报11.9元/股，成交3.0亿元。三生制药是一家主要致力于开发、生产和销售医药产品，产品包括重组人血小板生成素、肿瘤坏死因子α抑制剂以及重组人促红素等，销售市场涵盖国内以及斯里兰卡、多米尼加共和国和泰国等海外市场。此外，公司通过其子公司集思有限公司,香港三生医疗有限公司和沈阳三生制药有限责任公司也从事项目管理和咨询业务。截至2024年年报，三生制药营业总收入91.08亿元、净利润20.9亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/30145150039034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01530","BK1593","BK1161","BK1583"],"gpt_icon":0},{"id":"2531732707","title":"豫健生物、復星醫藥強強聯合，25億醫學城星未來基金正式設立","url":"https://stock-news.laohu8.com/highlight/detail?id=2531732707","media":"大河财立方","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531732707?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 12:51","pubTimestamp":1745988707,"startTime":"0","endTime":"0","summary":"大河财立方记者 裴熔熔4月30日，上海复星医药集团正式官宣：与豫健生物医药集团有限公司联合发起的医学城星未来基金正式设立，总规模25亿元。医学城星未来基金正是应势创设。联合出资人为豫健生物、复星医药和郑州航空港科创集团。强强联合，将世界级技术与产品导入中原医学科学城医学城星未来基金的设立，究竟会带来什么？","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430130547a46d2b69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430130547a46d2b69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2531954729","title":"四環醫藥(00460)出現大手賣出250萬股，成交價$0.73，涉資182.5萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2531954729","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531954729?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 11:04","pubTimestamp":1745982240,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在上午11:04出现大手卖出，成交量为250万，成交价为港币$0.73，涉资182.5万。至目前为止，股价无升跌，今日最高价为$0.76，而最低价为$0.73，总成交量为2.862千万股，总成交金额港币$2.127千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2504307057/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1515","BK1593","00460","BK1600"],"gpt_icon":0},{"id":"2531747910","title":"21健訊Daily | 接棒吳以芳，陳玉卿出任復星醫藥董事長；阿斯利康一季度收入135.88億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531747910","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531747910?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 09:33","pubTimestamp":1745976806,"startTime":"0","endTime":"0","summary":"政策动向海南：促进仿制药质量提升支持首仿品种加快注册上市4月29日，《海南省全面深化药品医疗器械化妆品监管改革促进医药产业高质量发展实施方案》对外发布。其中提出，促进仿制药质量提升。一是支持首仿品种加快注册上市。对首仿品种实施专人负责、主动对接、加强指导、全程服务，在审评审批、注册核查、产品检验等方面给予支持。二是加强委托生产监管。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504303394003434.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504303394003434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1829250122.USD","BK1593","BK4568","LU2417539215.USD","BK1515","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","LU0109394709.USD","BK4007","BK4585","02196","LU0320765992.SGD","AZN","LU0889565916.HKD","BK1191","BK4588"],"gpt_icon":0},{"id":"2531732054","title":"復星醫藥換帥：陳玉卿接棒吳以芳任董事長，吳以芳改任復星國際執行總裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2531732054","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531732054?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 21:05","pubTimestamp":1745931918,"startTime":"0","endTime":"0","summary":"在公布一季报之际，履职不到5年的吴以芳辞任复星医药董事长一职，现任复星国际高级副总裁接任董事长一职。4月29日晚间，复星医药（600196.SH；2196.HK）发布公告称，近日，董事会收到吴以芳、王可心的书面辞职函，因工作安排调整，吴以芳、王可心分别辞去公司董事长、联席董事长职务。根据公司章程规定，辞任自2025年4月29日生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202504293393218813.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202504293393218813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["00656","BK1191","02196","BK1515","BK1593","BK1230"],"gpt_icon":0},{"id":"2531473033","title":"復星醫藥控股企業簽訂合夥協議","url":"https://stock-news.laohu8.com/highlight/detail?id=2531473033","media":"格隆汇资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531473033?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 20:30","pubTimestamp":1745929807,"startTime":"0","endTime":"0","summary":"格隆汇4月29日丨复星医药(02196.HK)发布公告，2025年4月29日，公司控股企业苏州君明与河南复健、豫健生物、郑州航空港资本签订《合伙协议》，各方拟共同出资设立目标基金。目标基金将主要投资以中原地区为中心的医疗器械诊断、生命科学、创新药及其上下游产业链的创新型企业。目标基金计划募集资金人民币250,000万元，其中：苏州君明（作为LP）拟现金出资人民币49,000万元认缴目标基金中的等值财产份额。本次发起设立以中原地区为中心的医疗器械诊断、生命科学、创新药及其上下游产业链为主要投资方向的股权投资基金，有利于丰富集团创新技术和产品的培育和储备渠道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042920302094e7889d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042920302094e7889d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1593","BK1515"],"gpt_icon":0},{"id":"2531735364","title":"復星醫藥(02196)控股企業蘇州君明擬出資4.9億元參設私募股權投資基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2531735364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531735364?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 20:26","pubTimestamp":1745929572,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，2025 年 4 月 29 日，公司控股企业苏州君明与河南复健、豫健生物、郑州航空港资本签订《合伙协议》，各方拟共同出资设立目标基金。目标基金将主要投资以中原地区为中心的医疗器械诊断、生命科学、创新药及其上下游产业链的创新型企业。目标基金计划募集资金人民币25亿元，其中：苏州君明(作为 LP)拟现金出资人民币4.9亿元认缴目标基金中的等值财产份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0183","BK0028","BK0239","BK0187","BK1593","BK0188","BK0175","BK0196","BK0096","BK0012","600196","BK1515","BK0060","02196"],"gpt_icon":0},{"id":"2531613733","title":"復星醫藥(02196)控股子公司復宏漢霖與 Sandoz AG 簽訂《合作與許可協議》","url":"https://stock-news.laohu8.com/highlight/detail?id=2531613733","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531613733?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 20:21","pubTimestamp":1745929296,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，本公司控股子公司复宏汉霖与 Sandoz AG 签订《合作与许可协议》，由复宏汉霖授予 Sandoz AG 于许可区域及许可领域开发、生产及商业化其在研产品 HLX13的权利。HLX13系复宏汉霖自主研发的伊匹木单抗生物类似药，拟用于治疗黑色素瘤、肾细胞癌、结直肠癌、肝细胞癌、非小细胞肺癌、恶性胸膜间皮瘤及食管鳞状细胞癌。截至本公告日期，HLX13 于中国境内处于 I 期临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK1161","BK1593","BK0183","BK0196","BK0188","AG","02696","BK0239","BK0028","02196","BK0060","BK1191","BK4210","BK0096","BK1515","BK0012","BK0187","BK0175"],"gpt_icon":0},{"id":"2531736358","title":"復星醫藥控股子公司復宏漢霖與 Sandoz AG簽訂《合作與許可協議》","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736358","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531736358?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 20:21","pubTimestamp":1745929260,"startTime":"0","endTime":"0","summary":"复星医药子公司复宏汉霖与Sandoz AG签订协议，授权其在多个国家和地区开发、生产及商业化在研产品HLX13，用于治疗多种癌症。HLX13在中国处于I期临床研究阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429202714974a265b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429202714974a265b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","02696","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2531782649","title":"復星醫藥(02196)選舉陳玉卿擔任董事會董事長","url":"https://stock-news.laohu8.com/highlight/detail?id=2531782649","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531782649?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:42","pubTimestamp":1745926950,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 公布，因工作安排调整，吴以芳先生、王可心先生分别辞去公司董事长、联席董事长职务。根据《公司章程》的规定，董事长为公司的法定代表人，公司的法定代表人将变更为陈玉卿先生。同意聘任陈玉卿先生为公司授权代表，与公司联席公司秘书之一的陈秀玲女士共同履行联交所《上市规则》项下授权代表的有关职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02196","BK0187","BK0188","BK0239","BK0060","BK1191","BK0028","BK0012","BK0196","BK1515","BK0096","BK0175","BK1593","BK0183","600196"],"gpt_icon":0},{"id":"2531789040","title":"接棒吳以芳，陳玉卿出任復星醫藥(02196)董事長","url":"https://stock-news.laohu8.com/highlight/detail?id=2531789040","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531789040?lang=zh_tw&edition=fundamental","pubTime":"2025-04-29 19:14","pubTimestamp":1745925258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月29日，复星医药公布2025年首季度业绩报告。第一季度，复星医药实现营业收入人民币94.20亿元，归母净利润人民币7.65亿元，经营活动现金流人民币10.56亿元。同日，复星医药公布了董事会分工的调整。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0196","BK0028","BK1593","BK1191","BK0060","BK0183","02196","BK0187","BK0096","BK0188","BK1515","BK0239","BK0175","600196"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":130,"code":"91000000","status":"200"}]}}